Annexon reports Q4 2024 net loss $48.6M; cash $312M; key pipeline milestones for GBS and dry AMD

Annexon, Inc.

Cash $312.0M as of Dec 31, 2024; runway into 2H 2026.
Net loss $48.6M Q4 2024 vs $27.9M Q4 2023; R&D expense $43.4M.
Pre-BLA meeting for GBS drug ANX005 targeted 1H 2025; BLA submission planned.
Global registration path for ANX007 in dry AMD with GA; Phase 3 ARCHER II data expected 2H 2026.
ANX1502 oral C1s inhibitor POC trial ongoing; dataset in up to 7 CAD patients expected mid-2025.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.